Evidence map›Paper›PMID 41495750›Full record

ArticleWorld journal of surgical oncology2026

miR-146b-5p promotes prostate cancer progression by targeting and negatively regulating FOXO3 and its mechanism.

Baoji Xing, Meini Cen, Yin Yu, Feng Feng, Zhao Wang

Abstract read
In one paragraph

Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Baoji Xing *Department of Radiation Oncology, Harbin Medical University Cancer Hospital, Harbin, 150081, China.
Meini Cen *Department of Rehabilitation, The Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, 533000, China.
Yin YuDepartment of Urology Surgery, Xinchang Hospital of Traditional Chinese Medicine, Shaoxing, 312500, China.
Feng FengDepartment of Urology Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, No. 324, Jingwuweiqi Road, Huaiyin District, Jinan, Shandong Province, 252000, China. fengfengsdjn@163.com.
Zhao WangDepartment of Urology Surgery, The First Hospital of Hebei Medical University, No. 89, Donggang Road, Yuhua District, Shijiazhuang, Hebei Province, 050000, China. wangzhaodrsjz@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsTo investigate the expression and potential mechanism of action of miR-146b-5p in prostate cancer (PCa).

methodsQuantification of miR-146b-5p and FOXO3 expression by RT-qPCR was performed on 140 paired PCa and normal adjacent tissues. Kaplan-Meier curves and Cox regression models were used to analyze the relationship between miR-146b-5p expression and 5-year survival outcomes. In vitro experiments were performed in PC-3 and 22RV1 cells to explore the regulatory relationship between miR-146b-5p and FOXO3.

resultsmiR-146b-5p is markedly upregulated in PCa tissues and cell lines, exhibiting a significant correlation with tumor stage, Gleason score, lymph node metastasis, and unfavorable prognosis. miR-146b-5p overexpression promoted PCa cell proliferation, migration, and invasion, while inhibition exerted opposite effects. Bioinformatics prediction and dual-luciferase assay confirmed that miR-146b-5p directly targeted the 3'UTR of FOXO3, negatively regulating its expression. Rescue experiments demonstrated that silencing FOXO3 reversed the inhibitory effects of miR-146b-5p inhibitor on PCa cell malignancy.

conclusionsmiR-146b-5p drives PCa progression through the targeted downregulation of FOXO3, implicating it as a promising prognostic marker and therapeutic target.

Indexed as

Biomarkers, TumorForkhead Box Protein O3Gene Expression Regulation, NeoplasticMicroRNAsProstatic NeoplasmsAgedCell Line, TumorCell MovementCell ProliferationDisease ProgressionHumansMaleMiddle AgedNeoplasm InvasivenessPrognosisSurvival RateBiomarkers, TumorForkhead Box Protein O3FOXO3 protein, humanMicroRNAsMIRN146 microRNA, humanFOXO3miR-146b-5pPrognosisProstate cancer

Identifiers

PMID41495750
PMCPMC12870093

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.